Programmed cell death protein 1 or its ligand (PD-1/PD-L1) are both important regulators of the TME (95, 96), and the emergence of antibody-based ICB therapies against PD-1/PD-L1 has led to an improved immunotherapy method of several cancer types (97). The gene discussed is PDCD1; the disease is cancer.